Please assess the completion status of the following clinical trial:

Trial Title: Functional Respiratory Imaging and Orkambi in CF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of CF (homozygous for the F508del mutation must be present, this should be documented in the medical history).~* Age ≥ 12 years~* FEV1 \> 50%~* Signed informed consent. If patient is a minor, parents/guardians must give written informed consent~* Patient must be on a stable regimen of CF medication for 4 weeks prior to Visit~Exclusion Criteria:~* FEV1 \< 50%~* Anticipated requirement for hospitalization within the next three weeks~* History of pneumothorax within the past 6 months prior to Visit 1~* History of haemoptysis requiring embolization within the past 12 months prior to Visit 1~* Unable or unwilling to complete study visits or provide follow-up data as required per the study protocol~* Has taken Intravenous (IV) antibiotics within the past 4 weeks prior to Visit 1~* Has ongoing exacerbation or Allergic bronchopulmonary aspergillosis (ABPA)~* Pregnant or lactating female~* Posttransplant patients~* Patients with severe hepatic impairment

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Orkambi open-label arm (Type: EXPERIMENTAL): Open-label study: all subjects will receive Orkambi during 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).